What is the share price of Ajanta Pharma Limited (AJANTPHARM) today?
The share price of AJANTPHARM as on 10th September 2026 is ₹3520. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Ajanta Pharma Limited (AJANTPHARM) share?
The past returns of Ajanta Pharma Limited (AJANTPHARM) share are- Past 1 week: 0.65%
- Past 1 month: 0.33%
- Past 3 months: 15.13%
- Past 6 months: 18.00%
- Past 1 year: 36.48%
- Past 3 years: 104.44%
- Past 5 years: 148.47%
What are the peers or stocks similar to Ajanta Pharma Limited (AJANTPHARM)?
The peers or stocks similar to Ajanta Pharma Limited (AJANTPHARM) include:What is the dividend yield % of Ajanta Pharma Limited (AJANTPHARM) share?
The current dividend yield of Ajanta Pharma Limited (AJANTPHARM) is 0.78.What is the market cap of Ajanta Pharma Limited (AJANTPHARM) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Ajanta Pharma Limited (AJANTPHARM) is ₹45482.59 Cr as of 10th September 2026.What is the 52 week high and low of Ajanta Pharma Limited (AJANTPHARM) share?
The 52-week high of Ajanta Pharma Limited (AJANTPHARM) is ₹3796 and the 52-week low is ₹2329.90.What is the PE and PB ratio of Ajanta Pharma Limited (AJANTPHARM) stock?
The P/E (price-to-earnings) ratio of Ajanta Pharma Limited (AJANTPHARM) is 43.07. The P/B (price-to-book) ratio is 10.05.Which sector does Ajanta Pharma Limited (AJANTPHARM) belong to?
Ajanta Pharma Limited (AJANTPHARM) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Ajanta Pharma Limited (AJANTPHARM) shares?
You can directly buy Ajanta Pharma Limited (AJANTPHARM) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Ajanta Pharma Limited
AJANTPHARM Share Price
NSE₹3,520.000.41% (-14.40)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
AJANTPHARM Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
AJANTPHARM Performance & Key Metrics
AJANTPHARM Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 40.08 | 10.05 | 0.78% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 46.35 | 5.84 | 0.49% |
85%
Analysts have suggested that investors can buy this stock
from 13 analysts
Price Upside
Earnings Growth
Rev. Growth
AJANTPHARM Company Profile
Ajanta Pharma Limited is a specialty pharmaceutical company engaged in developing, producing and marketing a range of branded and generic formulations.
SUNPHARMA
PE Ratio
39.76
39.76
1Y Return
16.10%
16.10%
Buy Reco %
93.55
93.55
TORNTPHARM
PE Ratio
86.09
86.09
1Y Return
37.12%
37.12%
Buy Reco %
82.14
82.14
CIPLA
PE Ratio
29.83
29.83
1Y Return
12.14%
12.14%
Buy Reco %
62.86
62.86
ZYDUSLIFE
PE Ratio
22.17
22.17
1Y Return
7.59%
7.59%
Buy Reco %
57.69
57.69
LUPIN
PE Ratio
18.88
18.88
1Y Return
4.76%
4.76%
Buy Reco %
51.52
51.52
AJANTPHARM Sentiment Analysis
AJANTPHARM Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
AJANTPHARM Stock Summary · August 2026
Management said the company began FY27 on a strong footing, with revenue from operations up 25% year over year in Q1 and profit after tax rising 31% to Rs. 334 crores. The quarter combined broad-based domestic strength, where India branded sales grew 24% to Rs. 509 crores and continued to outperform the IPM, with mixed overseas performance: Africa remained robust and added three new launches, while Asia branded generics fell 16% because Middle East disruptions affected supply and dispatches. In the U.S., generic sales jumped 57% in the quarter, though management said that level would not persist as competition, price erosion and some share loss are expected to normalize growth. Profitability remained solid, with gross margin at 80% and EBITDA margin at 28%, even as personnel and R&D costs increased. Management emphasised continued investment in field force expansion, new therapeutic areas and product launches, while keeping capital returns healthy, including an interim dividend of Rs. 32 per share. Near term, the company reiterated its aim to sustain high-teen growth for the full year, with FY2027 EBITDA margin guided at 27% plus or minus 100 basis points and gross margin near 78%.
AJANTPHARM Stock Growth Drivers
AJANTPHARM Stock Growth Drivers
9Strong Consolidated Financial Performance and Profitability
The company delivered a strong start to FY27, with revenue from operations rising 25% year
Efficient Capital Allocation and Shareholder Returns
Capital efficiency remained strong, with return on capital employed at 37% and return on net
AJANTPHARM Stock Challenges
AJANTPHARM Stock Challenges
6Asia Branded Generics Disruption
The Asia branded generics business was the clearest near-term weakness, with revenue falling 16% year
U.S. Generic Normalization and Competitive Pressure
The U.S. generic business is expected to moderate after an unusually strong first quarter, which
AJANTPHARM Forecast
AJANTPHARM Forecasts
Price
Revenue
Earnings
AJANTPHARM Share Price Forecast
AJANTPHARM Share Price Forecast
2026
Current
₹3,540.00
Baseline
Forecast for Sep 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹3,540.00
Baseline
Forecast for Sep 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
AJANTPHARM Company Revenue Forecast
AJANTPHARM Company Revenue Forecast
2026
Current
₹5.62
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2026
Current
₹5.62
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
AJANTPHARM Stock EPS (Earnings Per Share) Forecast
AJANTPHARM Stock EPS (Earnings Per Share) Forecast
2026
Current
₹83.76
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹83.76
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
AJANTPHARM
AJANTPHARM
Income
Balance Sheet
Cash Flow
Quarterly Normal View
AJANTPHARM Income Statement
AJANTPHARM Income Statement
Quarterly Normal View
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,089.58 | 1,171.39 | 1,206.12 | 1,176.57 | 1,188.52 | 1,328.98 | 1,413.07 | 1,399.81 | 1,483.07 | 1,696.86 | ||||||||||
Operating & Other expenses | 775.76 | 814.57 | 875.47 | 825.30 | 873.26 | 951.30 | 1,025.90 | 992.60 | 1,088.23 | 1,202.38 | ||||||||||
EBITDA | 313.82 | 356.82 | 330.65 | 351.27 | 315.26 | 377.68 | 387.17 | 407.21 | 394.84 | 494.48 | ||||||||||
| Depreciation/Amortization | 34.25 | 33.97 | 34.39 | 35.97 | 39.78 | 41.29 | 42.97 | 43.51 | 45.37 | 44.50 | ||||||||||
| PBIT | 279.57 | 322.85 | 296.26 | 315.30 | 275.48 | 336.39 | 344.20 | 363.70 | 349.47 | 449.98 | ||||||||||
| Interest & Other Items | 1.53 | 0.73 | 6.02 | 7.91 | 6.07 | 5.26 | 3.39 | 5.10 | 2.36 | 3.18 | ||||||||||
| PBT | 278.04 | 322.12 | 290.24 | 307.39 | 269.41 | 331.13 | 340.81 | 358.60 | 347.11 | 446.80 | ||||||||||
| Taxes & Other Items | 75.32 | 76.35 | 73.76 | 74.51 | 44.15 | 75.79 | 80.62 | 84.83 | 80.41 | 112.58 | ||||||||||
| Net Income | 202.72 | 245.77 | 216.48 | 232.88 | 225.26 | 255.34 | 260.19 | 273.77 | 266.70 | 334.22 | ||||||||||
| EPS | 16.10 | 19.54 | 17.27 | 18.60 | 18.00 | 20.44 | 20.83 | 21.91 | 21.35 | 26.75 |
AJANTPHARM Company Updates
AJANTPHARM Stock Peers
AJANTPHARM Past Performance & Peer Comparison
AJANTPHARM Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Ajanta Pharma Limited | 43.07 | 10.05 | 0.78% |
| Sun Pharmaceutical Industries Ltd | 39.76 | 5.44 | 0.84% |
| Torrent Pharmaceuticals Ltd | 86.09 | 10.59 | 0.69% |
| Cipla Ltd | 29.83 | 3.35 | 0.91% |
AJANTPHARM Stock Price Comparison
Compare AJANTPHARM with any stock or ETFCompare AJANTPHARM with any stock or ETF
AJANTPHARM
AJANTPHARM Holdings
AJANTPHARM Shareholdings
AJANTPHARM Promoter Holdings Trend
AJANTPHARM Promoter Holdings Trend
Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 2.76%
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
AJANTPHARM Institutional Holdings Trend
AJANTPHARM Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
AJANTPHARM Shareholding Pattern
AJANTPHARM Shareholding Pattern
AJANTPHARM Shareholding History
AJANTPHARM Shareholding History
Foreign Institutions
Mutual Funds Invested in AJANTPHARM
Mutual Funds Invested in AJANTPHARM
No mutual funds holding trends are available
Top 5 Mutual Funds holding Ajanta Pharma Limited
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.3261% | Percentage of the fund’s portfolio invested in the stock 0.73% | Change in the portfolio weight of the stock over the last 3 months -0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 79/271 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.2321% | Percentage of the fund’s portfolio invested in the stock 1.00% | Change in the portfolio weight of the stock over the last 3 months 1.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 48/65 (+12) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.0501% | Percentage of the fund’s portfolio invested in the stock 1.98% | Change in the portfolio weight of the stock over the last 3 months -0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 9/66 (-1) |
Compare 3-month MF holding change on Screener
smallcases containing AJANTPHARM stock
smallcases containing AJANTPHARM stock
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Ajanta Pharma Limited
AJANTPHARM Events
AJANTPHARM Events
AJANTPHARM Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
AJANTPHARM has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.78%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹7.79 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
AJANTPHARM Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
AJANTPHARM has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.78%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹7.79 every year
AJANTPHARM Upcoming Dividends
AJANTPHARM Upcoming Dividends
No upcoming dividends are available
AJANTPHARM Past Dividends
AJANTPHARM Past Dividends
Cash Dividend
Ex DateEx DateAug 5, 2026
Interim 1
Interim 1 | Div/Share: ₹32.00
Dividend/Share
₹32.00
Ex DateEx Date
Aug 5, 2026
Cash Dividend
Ex DateEx DateNov 10, 2025
Interim 1
Interim 1 | Div/Share: ₹28.00
Dividend/Share
₹28.00
Ex DateEx Date
Nov 10, 2025
Cash Dividend
Ex DateEx DateNov 6, 2024
Interim 1
Interim 1 | Div/Share: ₹28.00
Dividend/Share
₹28.00
Ex DateEx Date
Nov 6, 2024
Cash Dividend
Ex DateEx DateFeb 8, 2024
Interim 2
Interim 2 | Div/Share: ₹26.00
Dividend/Share
₹26.00
Ex DateEx Date
Feb 8, 2024
Cash Dividend
Ex DateEx DateAug 4, 2023
Special
Special | Div/Share: ₹15.00
Dividend/Share
₹15.00
Ex DateEx Date
Aug 4, 2023
AJANTPHARM Stock News & Opinions
AJANTPHARM Stock News & Opinions
Articles & Videos
Spotlight
Spotlight
Ajanta Pharma Ltd drops for fifth straight sessionAjanta Pharma Ltd fell for a fifth straight session today. The stock is quoting at Rs 3582.5, down 1.57% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.32% on the day, quoting at 24173.35. The Sensex is at 77284.45, down 0.33%.Ajanta Pharma Ltd has gained around 5.8% in last one month.Meanwhile, Nifty Pharma index of which Ajanta Pharma Ltd is a constituent, has increased around 1.52% in last one month and is currently quoting at 26359.75, down 0.07% on the day. The volume in the stock stood at 30301 shares today, compared to the daily average of 1.1 lakh shares in last one month.The PE of the stock is 45.16 based on TTM earnings ending June 26.
2 weeks agoCapital Market - Live
Corporate
Corporate
Ravi Agrawal pledged Ajanta Pharma shares for business financing with Aditya Birla CapitalRavi Agrawal, trustee of Ravi Agrawal Trust, released a pledge on 6,910 equity shares of Ajanta Pharma Limited on August 14, 2026, citing business financing as the reason, according to a regulatory filing with the BSE and National Stock Exchange. Aditya Birla Capital Limited was the lender, and Barclays Securities (India) Private Limited acted as the depositary participant.
3 weeks agoCapital Market - Live
Corporate
Corporate
Ajanta Pharma promoter released pledge on shares to lenders including Deutsche InvestmentsRavi Agrawal, a promoter of Ajanta Pharma Limited, has released a pledge on 54,796 equity shares of the company, citing "Excess Pledge" as the reason. The release involved multiple transactions between August 6 and August 12, 2026, with lenders including Deutsche Investments India Pvt Ltd, Bajaj Finance Limited, INFINA FINANCE LIMITED, and Tata Capital Limited, facilitated through Barclays Securities (India) Private Limited.
3 weeks agoCapital Market - Live
Spotlight
Spotlight
Ajanta Pharma Ltd soars 0.37%, rises for fifth straight sessionAjanta Pharma Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 3526.8, up 0.37% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 1.13% on the day, quoting at 24493.35. The Sensex is at 78403.04, down 0.3%. Ajanta Pharma Ltd has risen around 4.54% in last one month. Meanwhile, Nifty Pharma index of which Ajanta Pharma Ltd is a constituent, has risen around 2.5% in last one month and is currently quoting at 26662.8, down 0.57% on the day. The volume in the stock stood at 45775 shares today, compared to the daily average of 1.15 lakh shares in last one month.The PE of the stock is 43.6 based on TTM earnings ending June 26.
1 month agoCapital Market - Live
Corporate
Corporate
Ajanta Pharma’s committee approved equity share allotment, boosting paid-up capitalAjanta Pharma Limited informed the BSE Limited and National Stock Exchange of India that its Nomination & Remuneration Committee has approved the allotment of 23,400 fully paid-up equity shares of Rs 2 each upon the exercise of options, increasing the company's paid-up capital to Rs 24,99,18,048 consisting of 12,49,59,024 equity shares.
1 month agoCapital Market - Live
Corporate
Corporate
Ajanta Pharma sets August 5, 2026, as record date for interim dividendAjanta Pharma Limited has set Wednesday, August 5, 2026, as the record date to determine shareholders eligible for the first interim dividend, according to a filing with the BSE Limited and National Stock Exchange of India.
1 month agoCapital Market - Live
Corporate
Corporate
Ajanta Pharma to table resultsAjanta Pharma will hold a meeting of the Board of Directors of the Company on 30 July 2026.
1 month agoCapital Market - Live
Spotlight
Spotlight
Ajanta Pharma Ltd gains for third consecutive sessionAjanta Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 3417.4, up 2.05% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.04% on the day, quoting at 24216.7. The Sensex is at 77693.16, up 0.16%. Ajanta Pharma Ltd has risen around 11.88% in last one month. Meanwhile, Nifty Pharma index of which Ajanta Pharma Ltd is a constituent, has risen around 5.67% in last one month and is currently quoting at 25674.1, down 0.32% on the day. The volume in the stock stood at 78457 shares today, compared to the daily average of 1.45 lakh shares in last one month.The PE of the stock is 44.47 based on TTM earnings ending March 26.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Corporate
Ajanta Pharma to conduct AGMAjanta Pharma announced that the 47th Annual General Meeting(AGM) of the company will be held on 16 July 2026.
2 months agoCapital Market - Live
Spotlight
Spotlight
Ajanta Pharma Ltd gains for third straight sessionAjanta Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 2993.7, up 1.56% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.18% on the day, quoting at 23373.6. The Sensex is at 74232.49, down 0.17%. Ajanta Pharma Ltd has slipped around 3.31% in last one month. Meanwhile, Nifty Pharma index of which Ajanta Pharma Ltd is a constituent, has slipped around 0.88% in last one month and is currently quoting at 24177.95, up 0.6% on the day. The volume in the stock stood at 69614 shares today, compared to the daily average of 1.65 lakh shares in last one month.The PE of the stock is 38.9 based on TTM earnings ending March 26.
3 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 14.04%, vs industry avg of 11.79%
Over the last 5 years, market share increased from 1% to 1.1%
Over the last 5 years, net income has grown at a yearly rate of 10.06%, vs industry avg of 10.54%